Treatment of carcinoma of the uterine cervix with concomitant cisplatin, 5-fluorouracil and split course hyperfractionated radiotherapy
| Autor: | N Tubiana-Mathieu, D.J Hadjadj, Christiane Lejeune, F. Delaby, Lucien Piana, Pascal Bonnier, X Murraciole, P. Juin |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
medicine.medical_specialty Antimetabolites Antineoplastic Radiation-Sensitizing Agents Time Factors medicine.medical_treatment Brachytherapy Population Disease-Free Survival Median follow-up Paraaortic lymph nodes Antineoplastic Combined Chemotherapy Protocols medicine Parametrium Humans education Aged Neoplasm Staging education.field_of_study business.industry Obstetrics and Gynecology Combination chemotherapy Middle Aged Survival Analysis Surgery Radiation therapy medicine.anatomical_structure Reproductive Medicine Chemotherapy Adjuvant Concomitant Uterine Neoplasms Carcinoma Squamous Cell Female Radiotherapy Adjuvant Fluorouracil Cisplatin business |
| Zdroj: | European journal of obstetrics, gynecology, and reproductive biology. 77(1) |
| ISSN: | 0301-2115 |
| Popis: | To improve local and systemic control of bulky (>4 cm) and/or advanced primary cancer of the uterine cervix, 35 patients were treated with concomitant cisplatin (CDDP), 5-fluorouracil (5-FU) and split course hyperfractionated radiotherapy. Radiation was administered to the pelvis in five-day courses at a dose of 1.5 Gy twice daily every 21 days until a median dose of 45 Gy was reached. 15 Gy more were administered to involved parametrium or central tumor by external radiotherapy or brachytherapy. The irradiated zone was extended to include paraaortic lymph nodes if necessary. CDDP was administered at a dose of 20 mg m −2 and 5 FU at a dose of 500 mg m −2 from day one to day five of each course. The median number of combined treatment courses per patient was four (1–6). Local responses were obtained in 19 out of 24 patients in whom evaluation was feasible (i.e. who did not undergo surgery prior to combined therapy). Median survival was not attained with a median follow up of 33 months, three year overall survival was 62% and 52% in patients with local control and in the whole population respectively. Several patients with stage III and IV tumors achieved a very long survival. Acute toxicity was manageable but three patients required surgical repair of late radiation complications. This combined chemotherapy and radiotherapy resulted in good local control and did not rule out surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect